Drug:
Reaction: MYELOSUPPRESSION
20250101 - 20251231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 25124559 |
CN |
72 | 2 |
Myelosuppression, |
||||
| 102 | 25124567 |
CN |
||
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 103 | 25124988 |
CN |
||
Myelosuppression, Hypoaesthesia, Hypoaesthesia, Asthenia, Off label use, |
||||
PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 104 | 25125050 |
CN |
||
Myelosuppression, |
||||
PACLITAXEL, PACLITAXEL, CISPLATIN, CISPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 105 | 25125628 |
CN |
45 | |
Myelosuppression, Thrombocytopenia, Aspartate aminotransferase increased, Alanine aminotransferase increased, Platelet count decreased, Lymphocyte count decreased, |
||||
OSIMERTINIB, |
||||
| 106 | 25125633 |
CN |
39 | 1 |
Myelosuppression, |
||||
BENDAMUSTINE HCL, ETOPOSIDE, ETOPOSIDE, CYTARABINE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE, |
||||
| 107 | 25125928 |
CN |
65 | |
Myelosuppression, |
||||
CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, |
||||
| 108 | 25125988 |
US |
||
Myelosuppression, |
||||
ABEMACICLIB, |
||||
| 109 | 25126000 |
CN |
||
Myelosuppression, Off label use, |
||||
ABEMACICLIB, ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 110 | 25115717 |
CN |
73 | |
Myelosuppression, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 111 | 25115820 |
CN |
73 | |
Myelosuppression, |
||||
ZANUBRUTINIB, |
||||
| 112 | 25115940 |
CN |
72 | |
Myelosuppression, |
||||
PACLITAXEL, PACLITAXEL, |
||||
| 113 | 25116074 |
CN |
35 | 2 |
Myelosuppression, |
||||
DENOSUMAB, SACITUZUMAB GOVITECAN, LEUPROLIDE ACETATE, |
||||
| 114 | 25116151 |
CN |
34 | |
Myelosuppression, |
||||
CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 115 | 25116548 |
JP |
29 | 1 |
Off label use, Testicular neoplasm, Myelosuppression, Pancreatitis, Anaemia, Platelet count decreased, Neutrophil count decreased, Febrile neutropenia, Scleroderma-like reaction, Drug level increased, Drug interaction, Cytomegalovirus infection, |
||||
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, METHYLPREDNISOLONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ETOPOSIDE, ETOPOSIDE, CISPLATIN, BLEOMYCIN, BLEOMYCIN SULFATE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 116 | 25117082 |
CN |
42 | 2 |
Myelosuppression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE, |
||||
| 117 | 25117261 |
CN |
55 | |
Myelosuppression, Anaemia, |
||||
OLAPARIB, |
||||
| 118 | 25117821 |
CN |
5 | 2 |
Myelosuppression, |
||||
NAXITAMAB, IFOSFAMIDE, ETOPOSIDE, |
||||
| 119 | 25117929 |
CN |
39 | 2 |
Myelosuppression, |
||||
| 120 | 25118015 |
CN |
15 | 1 |
Myelosuppression, Hepatic function abnormal, Drug-induced liver injury, |
||||
CYTARABINE, CYTARABINE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, LEUCOVORIN CALCIUM, |
||||
| 121 | 25118193 |
CN |
52 | |
Myelosuppression, |
||||
OSIMERTINIB, |
||||
| 122 | 25118220 |
CN |
57 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, CARBOPLATIN, |
||||
| 123 | 25118222 |
CN |
49 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, FLUOROURACIL, PACLITAXEL, |
||||
| 124 | 25118225 |
CN |
57 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 125 | 25118768 |
CN |
||
Myelosuppression, Off label use, |
||||
CEFTOBIPROLE MEDOCARIL SODIUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 126 | 25119332 |
CN |
55 | 2 |
Myelosuppression, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, PACLITAXEL, PACLITAXEL, |
||||
| 127 | 25119638 |
CN |
61 | 1 |
Myelosuppression, Intentional product use issue, |
||||
DARATUMUMAB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 128 | 25119964 |
CN |
7 | 2 |
Myelosuppression, Infection, Pyrexia, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, MESNA, MESNA INJECTION, MESNA, MESNA INJECTION, MESNA, MESNA INJECTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, |
||||
| 129 | 25120487 |
CN |
41 | 2 |
Myelosuppression, |
||||
SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, SACITUZUMAB GOVITECAN, ROMIPLOSTIM, |
||||
| 130 | 25120498 |
CN |
42 | 2 |
Myelosuppression, |
||||
| 131 | 25120608 |
CN |
57 | |
Myelosuppression, |
||||
PACLITAXEL, PACLITAXEL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 132 | 25120615 |
CN |
55 | |
Myelosuppression, Prescribed overdose, |
||||
| 133 | 25120632 |
CN |
71 | |
Myelosuppression, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 134 | 25120685 |
CN |
60 | 1 |
Myelosuppression, |
||||
OBINUTUZUMAB, |
||||
| 135 | 25109964 |
CN |
59 | |
Myelosuppression, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, |
||||
| 136 | 25110042 |
CN |
8 | 1 |
Myelosuppression, |
||||
IFOSFAMIDE, IFOSFAMIDE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 137 | 25110305 |
CN |
38 | 2 |
Myelosuppression, |
||||
RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DEXTROSE MONOHYDRATE, DEXTROSE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 138 | 25110404 |
CN |
53 | 1 |
Drug-induced liver injury, Myelosuppression, |
||||
OXALIPLATIN, CAPECITABINE, |
||||
| 139 | 25110493 |
CN |
73 | |
Myelosuppression, Pneumonia, Pleural effusion, Dyspnoea exertional, Chest discomfort, Peripheral swelling, |
||||
PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 140 | 25110592 |
US |
75 | 2 |
Neoplasm progression, Febrile neutropenia, Myelosuppression, Drug ineffective for unapproved indication, Infection, |
||||
ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, CARBOPLATIN, THIOTEPA, |
||||
| 141 | 25110604 |
CN |
48 | 1 |
Myelosuppression, Neutrophil count decreased, Granulocyte count decreased, |
||||
| 142 | 25110623 |
CN |
62 | 2 |
Myelosuppression, |
||||
VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, |
||||
| 143 | 25110629 |
US |
53 | 2 |
Septic shock, Myelosuppression, Febrile neutropenia, Infection, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, METHOTREXATE, METHOTREXATE SODIUM, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, CISPLATIN, CARBOPLATIN, THIOTEPA, |
||||
| 144 | 25110983 |
US |
75 | 2 |
Febrile neutropenia, Infection, Myelosuppression, Drug ineffective, |
||||
THIOTEPA, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, ETOPOSIDE, CARBOPLATIN, |
||||
| 145 | 25111105 |
US |
119 | 1 |
Myelosuppression, Febrile neutropenia, Infection, Sepsis, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 146 | 25111171 |
US |
69 | 2 |
Myelosuppression, Device related infection, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 147 | 25111284 |
US |
36 | 1 |
Myelosuppression, Seizure, Hyponatraemia, |
||||
ETOPOSIDE, TEMOZOLOMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 148 | 25111296 |
US |
53 | 2 |
Myelosuppression, Septic shock, Infection, Sepsis, Febrile neutropenia, |
||||
TEMOZOLOMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, |
||||
| 149 | 25111396 |
CN |
61 | 2 |
Myelosuppression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 150 | 25111554 |
US |
210 | 1 |
Febrile neutropenia, Infection, Myelosuppression, |
||||
ETOPOSIDE, TEMOZOLOMIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 151 | 25111568 |
US |
31 | 1 |
Myelosuppression, Infection, Febrile neutropenia, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, ETOPOSIDE, TEMOZOLOMIDE, |
||||
| 152 | 25111698 |
CN |
62 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, PERTUZUMAB, |
||||
| 153 | 25111708 |
CN |
65 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, PERTUZUMAB, PACLITAXEL, |
||||
| 154 | 25111709 |
CN |
50 | 2 |
Myelosuppression, Nausea, |
||||
TRASTUZUMAB, CARBOPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, PERTUZUMAB, |
||||
| 155 | 25112018 |
US |
119 | 1 |
Septic shock, Myelosuppression, Febrile neutropenia, Infection, Sepsis, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 156 | 25112706 |
ES |
55 | 2 |
Myelosuppression, Haemolytic anaemia, Off label use, |
||||
LINEZOLID, LINEZOLID, LINEZOLID, BELIMUMAB, |
||||
| 157 | 25112795 |
CN |
||
Myelosuppression, |
||||
CISPLATIN, |
||||
| 158 | 25112796 |
CN |
||
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 159 | 25112944 |
CN |
66 | 1 |
Myelosuppression, Therapy partial responder, Hypoaesthesia, Eastern Cooperative Oncology Group performance status abnormal, Malignant neoplasm progression, Product use in unapproved indication, |
||||
PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN, TRASTUZUMAB, |
||||
| 160 | 25113257 |
CN |
44 | 2 |
Nausea, Vomiting, Dysphagia, Myelosuppression, |
||||
EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 161 | 25113967 |
CN |
66 | 2 |
Myelosuppression, Product use in unapproved indication, |
||||
FRUQUINTINIB, |
||||
| 162 | 25114013 |
US |
65 | 1 |
Myelosuppression, Device related infection, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 163 | 25114664 |
CN |
71 | 1 |
Myelosuppression, |
||||
DENOSUMAB, ETOPOSIDE, |
||||
| 164 | 25114859 |
CN |
62 | 1 |
Thrombocytopenia, Leukopenia, Myelosuppression, Haemoglobin abnormal, Product use issue, |
||||
IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, FLUOROURACIL, OXALIPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 165 | 25114885 |
CN |
43 | 1 |
Hospitalisation, Myelosuppression, |
||||
IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, FLUOROURACIL, |
||||
| 166 | 25115491 |
CN |
60 | 1 |
Myelosuppression, |
||||
DARATUMUMAB, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 167 | 25115493 |
NP |
69 | 1 |
Dehydration, Myelosuppression, Stomatitis, Urinary tract infection, Accidental overdose, Hypertransaminasaemia, Inappropriate schedule of product administration, |
||||
METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 168 | 25109645 |
CN |
50 | |
Myelosuppression, |
||||
| 169 | 25109684 |
CN |
51 | |
Myelosuppression, |
||||
PACLITAXEL, |
||||
| 170 | 25109704 |
CN |
51 | |
Myelosuppression, |
||||
SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 171 | 25109712 |
CN |
67 | |
Myelosuppression, Neutrophil count decreased, White blood cell count decreased, Pyrexia, Skin injury, Breath sounds abnormal, Scar, |
||||
PACLITAXEL, |
||||
| 172 | 25107616 |
CN |
84 | 2 |
Myelosuppression, |
||||
BEVACIZUMAB, |
||||
| 173 | 25107628 |
CN |
61 | 1 |
Myelosuppression, |
||||
BEVACIZUMAB, |
||||
| 174 | 25108801 |
CN |
2 | |
Myelosuppression, |
||||
BORTEZOMIB, |
||||
| 175 | 25108919 |
CN |
62 | 2 |
Myelosuppression, |
||||
FRUQUINTINIB, |
||||
| 176 | 25102626 |
CN |
27 | |
Myelosuppression, |
||||
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, OXALIPLATIN, OXALIPLATIN, FLUOROURACIL, FLUOROURACIL, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 177 | 25102693 |
CN |
72 | |
Myelosuppression, |
||||
CAPECITABINE, CAPECITABINE, |
||||
| 178 | 25102891 |
CN |
74 | |
Myelosuppression, |
||||
CISPLATIN, PEMETREXED DISODIUM, PEMETREXED, |
||||
| 179 | 25103172 |
CN |
49 | 1 |
Myelosuppression, Off label use, |
||||
CEFTOBIPROLE MEDOCARIL SODIUM, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 180 | 25103598 |
CN |
50 | 1 |
Myelosuppression, Swelling face, |
||||
VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
| 181 | 25103737 |
CN |
49 | 2 |
Myelosuppression, White blood cell count decreased, Granulocyte count decreased, |
||||
OBINUTUZUMAB, BENDAMUSTINE HYDROCHLORIDE, |
||||
| 182 | 25103952 |
CN |
53 | 1 |
Myelosuppression, |
||||
CARFILZOMIB, CARFILZOMIB, POMALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 183 | 25103960 |
CN |
56 | |
White blood cell count decreased, Neutrophil count decreased, Anaemia, Myelosuppression, Platelet count decreased, |
||||
OSIMERTINIB, FOLIC ACID, |
||||
| 184 | 25104189 |
CN |
61 | 2 |
Myelosuppression, |
||||
TRASTUZUMAB, PACLITAXEL, |
||||
| 185 | 25104206 |
JP |
80 | |
Myelosuppression, |
||||
DURVALUMAB, DURVALUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, CISPLATIN, |
||||
| 186 | 25104261 |
CN |
47 | 2 |
Myelosuppression, Epistaxis, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, BEVACIZUMAB, |
||||
| 187 | 25104337 |
US |
36 | 1 |
Myelosuppression, Seizure, Hyponatraemia, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 188 | 25104345 |
US |
31 | 1 |
Infection, Febrile neutropenia, Myelosuppression, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 189 | 25104347 |
US |
75 | 2 |
Febrile neutropenia, Myelosuppression, Infection, Drug ineffective, Disease progression, Off label use, |
||||
ETOPOSIDE, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, CARBOPLATIN, THIOTEPA, |
||||
| 190 | 25104527 |
JP |
41 | 2 |
Myelosuppression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 191 | 25104662 |
US |
119 | 1 |
Sepsis, Infection, Febrile neutropenia, Myelosuppression, |
||||
ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, |
||||
| 192 | 25104792 |
CN |
22 | 1 |
Disseminated varicella zoster virus infection, Multiple organ dysfunction syndrome, Cardiac arrest, Bacterial infection, Coagulopathy, Hyponatraemia, Hyperlactacidaemia, Haematological infection, Septic shock, Anuria, Myelosuppression, Respiratory failure, Haemorrhage, Arrhythmia, |
||||
METHYLPREDNISOLONE, METHYLPREDNISOLONE, |
||||
| 193 | 25105225 |
CN |
41 | 2 |
Myelosuppression, Off label use, Disease progression, Abdominal pain, Decreased appetite, |
||||
GEMCITABINE HYDROCHLORIDE, |
||||
| 194 | 25105907 |
CN |
||
Myelosuppression, |
||||
GEMCITABINE HYDROCHLORIDE, CISPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 195 | 25106011 |
CN |
||
Myelosuppression, |
||||
OXALIPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, DEXTROSE MONOHYDRATE, DEXTROSE, |
||||
| 196 | 25106065 |
JP |
||
Myelosuppression, Haematotoxicity, |
||||
PALBOCICLIB, |
||||
| 197 | 25106074 |
JP |
75 | 2 |
Myelosuppression, Anaemia, Platelet count decreased, |
||||
PALBOCICLIB, |
||||
| 198 | 25106092 |
CN |
61 | 2 |
Myelosuppression, Asthenia, |
||||
CYTARABINE, |
||||
| 199 | 25106140 |
CN |
||
Myelosuppression, |
||||
PACLITAXEL, |
||||
| 200 | 25106564 |
CN |
70 | 2 |
Myelosuppression, |
||||
ERIBULIN MESYLATE, TRASTUZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28